United States: Telemedicine And Digital Health Companies Will Benefit From Newly-Proposed Fraud And Abuse Waivers

The OIG recently released proposed revisions to the Anti-Kickback Statute (AKS) and Civil Monetary Penalties (CMP) Law. Several of these changes, if finalized, will directly benefit companies offering telemedicine and digital health items or services, remote patient monitoring (RPM), and Chronic Care Management (CCM) services. The key changes relevant to such digital health issues are summarized below.

Incentives for Patient Engagement and Preventative Tools, Items, and Services

The AKS and CMP Law inhibit the effectiveness and widespread use of certain patient engagement and support tools, a challenge familiar to the telemedicine and digital health industry. OIG has issued advisory opinions approving certain digital health arrangements where patients receive free technology, but this proposal would codify that practice as an established exception. Companies should welcome the OIG's new AKS safe harbor for patient engagement tools and support.

Currently, the proposed safe harbor is limited to tools and support provided within the context of a value based enterprise (VBE), but the OIG is seeking public comment on whether it should extend this safe harbor to services outside VBEs.  For example, pharmaceutical manufacturers, distributors, durable medical equipment, orthotics and supplies (DMEPOS) suppliers and laboratories are not included in VBEs, and they may certainly want to offer meaningful patient support technology to the patients they serve.

CCM and RPM companies should be particularly interested in the "monitoring tools" included in the definition of patient engagement tools and support.  This definition would include more than mere clinically-based tools, such as social determinant tools and support.  Such social determinant tools are often used by virtual care companies who seek to deliver a more holistic approach to patient health and wellness. The definition is as follows:

"in-kind, preventive item, good, or service, or an in-kind items, goods, or services such as health-related technology, patient health-related monitoring tools and services, or supports and services designed to identify and address a patient's social determinants of health."

OIG intentionally did not define "preventive," in order to allow for continual evolvement and innovation in clinical care technology and approaches. The determination whether or not an item or service is "preventive" requires a clinician's professional judgment. If a question arises regarding applicability of this safe harbor to any given item or service, clinicians must be able to articulate why the item or service is "preventive" in nature.

In addition, the tool must have a direct connection to the coordination and management of patient care, and cannot include gift cards, cash, and any cash equivalent.  OIG is seeking public comment as to whether it should change "direct connection" to a "reasonable connection," and if OIG should include gifts cards, cash, etc. within the scope of the safe harbor.

As we expected, these digital health tools cannot be used for marketing/patient recruitment.  They must be medically necessary and recommended by the patient's licensed health care practitioner.  The tools must also advance one of several enumerated goals (e.g., care plan or drug regimen adherence, disease state management, outcome improvement and/or patient safety). As an example of such tools, the OIG specifically cited wearable monitoring devices, such as a smart watch or tracker that collects and transmits data.

Waivers of Patient Co-Payments for CCM and RPM Services

The proposed patient engagement safe harbor would not allow routine waivers of patient cost-sharing amounts. The government has long prohibited such waivers. However, OIG is open to consider a limited waiver of patient cost-sharing only for CCM and RPM services. This is due to the opinion that sometimes the expense to collect co-pays for these monthly services can exceed the actual amounts collected from beneficiaries. Thus, the OIG is seeking public comment on whether or not it should create a safe harbor to allow waivers of cost sharing for CCM and RPM services. Should any such safe harbor be finalized, the OIG predicts it will be similar in form to the patient engagement safe harbor.

Safe Harbor for End Stage Renal Disease Telehealth Technology

As part of the Bipartisan Budget Act of 2018, Medicare allowed beneficiaries to elect to receive certain End Stage Renal Disease (ESRD) support services via telemedicine in their home and created a statutory exception to the definition of remuneration under the CMP law for telehealth technologies used in connection with such ESRD services. The OIG has now proposed a regulation further interpreting this statutory exception.

The proposed regulation aligns the definition of "telehealth technologies" with Medicare's existing definition, which requires the use of an interactive audio-visual telecommunication system. For purposes of this ESRD safe harbor, OIG stated that smartphones allowing for two-way interactive communication through secure, video conference applications are included in the definition (i.e., they are not considered merely a "telephone").

The proposed regulation applies the following requirements to the telehealth technology, some of which were already contained in the statutory exception:

  1. Must be furnished by a provider or dialysis facility currently providing the in-home dialysis or other ESRD services. The OIG reasons that the provision of technology by non-treating providers can raise the risk of patient steering.
  2. Must not be advertised and solicited. The OIG provides no additional insight as to meaning of these terms other than they should be interpreted consistent with common health care industry usage.
  3. Contribute substantially to the ESRD telehealth services
    1. Not of excessive value, (i.e. if a $300 smart phone can achieve the necessary purpose, a $600 smartphone should not be provided); and
    2. Not duplicative of technology already available to the patient.
  4. Providers may not bill Federal health care programs for the telehealth technologies or otherwise shift the costs to such programs.

The OIG remains concerned that such safe harbors can improperly influence a patient's choice of ESRD provider (e.g., patients would select those providers who offer the most incentives).  Thus, OIG is seeking public comment on whether or not it should add more safeguards to the safe harbor (e.g., requiring the provider to retain ownership in any hardware and to retrieve it when it is no longer needed by the patient, limiting any non-telehealth related benefit of the technology to one with de minimus value).  And yet, the OIG is simultaneously seeking comments if it should further expand this exception to include suppliers in addition to ESRD providers and renal dialysis facilities. Such expanded definition likely better aligns with Congress' legislative intent behind the BBA goals to expand patient access to in-home ESRD care.

While this exception is limited to technologies provided to in-home ESRD patients, the OIG noted that arrangements involving the provision of a broader scope of telehealth technologies may still be protected under other safe harbors or the newly-proposed safe harbor for patient engagement and support.

How to Submit Comments on the Proposed Rule

Providers, technology companies, and entrepreneurs interested in telehealth should consider submitting comments to the proposed rule anonymously or for attribution– via electronic submission at  this link. Alternatively, commenters may submit comments by regular, express, or overnight mail to: Office of Inspector General, Department of Health and Human Services, Attention: OIG-0936-AA10-P, Room 5521, Cohen Building, 330 Independence Avenue SW, Washington, DC 20201.  Be sure to submit all comments before December 31, 2019. If submitting via mail, please be sure to allow time for OIG to receive comments before the closing date.


The OIG proposed a number of exciting, patient-oriented opportunities to expand virtual care and digital health services for Medicare beneficiaries, particularly for CCM, RPM, and telehealth services.  Interested companies and industry advocates should use this opportunity to make their voice heard by submitting public comments. We will continue to monitor OIG for any rule changes or guidance that affect or improve telemedicine and digital health opportunities.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions